中国药物警戒 ›› 2019, Vol. 16 ›› Issue (1): 6-12.

• 基础与临床研究 • 上一篇    下一篇

注射用重组人凝血因子VIII食蟹猴单次及反复给药毒性研究

范潇予1, 王艺诺1,2, 滑曼曼3, 卢晓晨3, 王江雪3, 单永超3, 魏金锋1,3, 靳洪涛1,3,*   

  1. 1中国医学科学院药物研究所/新药安全评价研究中心,北京 100050;
    2北京诺思兰德生物技术股份有限公司,北京 100085;
    3北京协和建昊医药技术开发有限责任公司,北京 100176
  • 收稿日期:2018-10-23 修回日期:2019-02-18 出版日期:2019-01-20 发布日期:2019-02-18
  • 通讯作者: 靳洪涛,男,博士,副研究员·硕导,药物毒理学。E-mail:jinhongtao@imm.ac.cn
  • 作者简介:范潇予,女,在读硕士,药物毒理学。
  • 基金资助:
    国家自然科学基金(81773996):小分子物质5-HMF及其二聚体OMBF作为变应原的毒性与机制研究;重大新药创制专项(2018ZX09201017-005):吸入毒性和儿童用药等特色创新药物安全性评价关键技术研究

Single and Repeated Dose Toxicity Study of Recombinant Human Factor VIII for Injection in Macaca Fascicularis

FAN Xiaoyu1, WANG Yinuo1,2, HUA Manman3, LU Xiaochen3, WANG Jiangxue3, SHAN Yongchao3, WEI Jinfeng1,3, JIN Hongtao1,3,*   

  1. 1Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, China;
    2Beijing Northland Biotech. Co., Ltd, Beijing 100085, China;
    3Beijing Union-Genius Pharmaceutical Technology Co., Ltd., Beijing 100176, China
  • Received:2018-10-23 Revised:2019-02-18 Online:2019-01-20 Published:2019-02-18

摘要: 目的 通过单次及30天重复给予食蟹猴静脉注射重组人凝血因子Ⅷ,观察可能出现的毒性反应性质和程度,为临床安全用药提供参考资料。方法 急性毒性实验采用致死剂量法,一次静脉给药后,观察食蟹猴可能出现的急性毒性反应。长期毒性实验中连续给药30天,停药后恢复期观察4周,期间观察食蟹猴各项指标变化。结果 急性毒性实验除61 250 IU·kg-1组动物给药后第14天乳酸脱氢酶(LDH)与药前相比升高外,其他均未见明显异常。30天连续给药实验中,出现与凝血因子Ⅷ抗体和抑制物相关的临床症状,未发现与给药明确相关的毒性病理改变。结论 食蟹猴单次静脉注射用重组人凝血因子Ⅷ的最大耐受剂量大于61 250 IU·kg-1;30天重复给药未见明显毒性反应剂量(NOAEL)为250 IU·kg-1。

关键词: 食蟹猴, 凝血因子Ⅷ, 急性毒性, 反复给药毒性

Abstract: Objective In the experiment, recombinant human coagulation factor VIII is administered intravenously to Macaca fascicularis in a single and 30-day period to observe the potential toxicity and extent of the toxicity, and also the development and recovery of toxicity, so as to provide reference information for the clinical dose design and clinical adverse drug reactions monitoring. Methods The acute toxicity test was performed by lethal dose method. After single intravenous administration, the acute toxicity in Macaca fascicularis was observed. In the 30 days' repeated-dose toxicity experiment, 1 time/day administration was carried out for 30 days, and the recovery period was four weeks. Changes in various indexes of the Macaca fascicularis were observed. Results In the acute toxicity test, only the 61 250 IU·kg-1 group animals were observed lactate dehydrogenase (LDH) increased compared with self-controls before drug given. In the 30-day administration experiment, clinical symptoms associated with factor VIII antibodies and inhibitors, such as prolongation of APTT, hemorrhage, A/G reduction were found, and there were no toxic pathological changes clearly associated with administration. Also, no delayed or accumulation toxicity were observed. Conclusion The maximum tolerated dose of recombinant human factor VIII for single intravenous injection to Macaca fascicularis is greater than 61 250 IU·kg-1. No observed adverse effect level (NOAEL) of recombinant human factor VIII is 250 IU·kg-1 for the 30 days of repeated administration.

Key words: Macaca fascicularis, factor VIII, acute toxicity, repeated dose toxicity

中图分类号: